Tag: Based on the content describing a Phase 2 trial combining the oncolytic virus RP1 and the PD-1 inhibitor nivolumab for treatment-resistant melanoma

Early-phase clinical data are increasingly shedding light on groundbreaking therapeutic strategies that harness the body’s own immune defenses to combat ...